Enanta Pharmaceuticals Inc., of Watertown, Mass., reported Phase II data showing that different doses of ABT-450/r, its lead candidate in its hepatitis C virus (HCV) protease inhibitor collaboration with Abbott, of Abbott Park, Ill., plus ABT-333 and ribavirin administered for 12 weeks produced sustained virological response at 12 weeks post-treatment (SVR12) in 93 percent and 95 percent of treatment-naïve genotype 1 patients.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST